Navigation Links
GTC Biotherapeutics to Webcast Corporate Presentation at the C.E.,Unterberg, Towbin Emerging Growth Life Opportunities Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)--Jul 5, 2007 - GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Wednesday, July 11, 2007 at 9:00 a.m. during the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference. The conference is being held at the Mandarin Oriental Hotel, New York, New York from July 10 - 12, 2007.

The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. The replay can be accessed from this same website and will be available within 24 hours of the presentation.

About GTC Biotherapeutics

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. ATryn(R), GTC's recombinant form of human antithrombin, is approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal.

LEO Pharma A/S, ATryn(R)'s commercial and development partner in Europe, Canada, and the Middle East, is in the process of launching in the approved indication and recruiting patients into a Phase II dose ranging study for the treatment of disseminated intravascular coagulation associated with severe sepsis. GTC is conducting a Phase III study of ATryn(R) for use in the United States in hereditary antithrombin deficiency patients undergoing high risk surgical and childbirth procedures. In addition, GTC has established a strategic collaboration with LFB Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors.


'"/>




Page: 1 2

Related medicine technology :

1. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
2. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
3. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
4. Iomai to Announce Results From Phase 1 Influenza Trial and Host Webcast Tomorrow
5. Isis Pharmaceuticals Announces Its Participation at the Upcoming ACC 56th Annual Scientific Session in New Orleans and Its Live Analyst/Investor Webcast Presentation
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
9. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
Post Your Comments:
(Date:1/23/2015)... , Jan. 23, 2015  CytoSorbents Corporation (NASDAQ CM: ... CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation ... receipt of $385,642, net of transaction costs, in ... Technology Business Tax Certificate Transfer Program sponsored by ...
(Date:1/22/2015)... CLEVELAND , Jan. 22, 2015  ViewRay™, a privately ... entered into an exclusive distributor agreement with ITOCHU Corporation ... radiation therapy system for the treatment of cancer in ... (me-rid-i-an) system, is the world,s first and only MRI-guided ...
(Date:1/22/2015)...  Amgen (NASDAQ: AMGN ) today announced that it will ... Tuesday, Jan. 27, 2015, after the close of the U.S. financial ... the investment community at 2 p.m. PT. Participating in the call ... chief executive officer, and other members of Amgen,s senior management team. ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2
... 8 Group Practice Forum (GPF), an independent network ... Fromer-GPF Patient Journey , a proprietary workflow solution designed ... patient care.  The Journey was developed by the ... FAAFP, who also serves as Assistant Clinical Professor of Family ...
... Protectus Medical Devices, Inc. (OTCQB: PTMD), developer and marketer of innovative safety ... US Patent and Trademark Office on its patent application describing a spring-activated, ... it becoming the gold standard in safety syringe devices.  , ... Dr. John Salstrom , CEO, ...
Cached Medicine Technology:Group Practice Forum Launches Fromer-GPF Patient Journey Providing Physicians with Simple Solutions to Improve Patient Care 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 2US Patent Allowed for Spring Action That Separates Protectus Innovative Safety Syringe From All Others 3
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... released a new blog post presenting the basic features of ... an accidental death and dismemberment rider for a car insurance ... benefits if the insured dies in an accident. Accidental death ... insurance. , AD&D is not expensive and can be ...
(Date:1/22/2015)... 2015 Yesterday, Senator Holly Mitchell ... Kristin Olsen (R-Modesto) were honored by the California ... biotechnology, biomedical science, medical device and pharmaceutical innovation ... the “2014 Life Sciences Champion” award from CHI ...
(Date:1/22/2015)... Four years since the release of their debut recording ... marriage of Avasa & Matthew Love – the duo are pleased ... release through White Swan Records on February 24, 2015. , THE ... path available to all of us to walk out of the ...
(Date:1/22/2015)... January 22, 2015 As interest in the ... care gains momentum worldwide, Rev. Eric J. Hall , ... Network (HCCN), will be the keynote speaker on January ... Israel’s public health system. , The conference, “Hope and Resilience: ...
Breaking Medicine News(10 mins):Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 2Health News:California Biomedical Community Honors Senator Holly Mitchell, Assemblymembers Susan Bonilla & Kristin Olsen 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3
... discussions with FDA -, MENLO PARK, Calif., Dec. ... of customizable drug-eluting stent (DES),systems, today announced that it ... for CE Mark approval of its Custom NX DES,System., ... dossier and the,drug formulation submission from Biosensors International Group. ...
... ST. PAUL (December 26, 2007) University of Minnesota ... researchers have discovered a new fast-acting antidote to cyanide ... those who are exposed to the chemical namely ... cyanide antidotes work slowly and are ineffective when administered ...
... hay fever and other allergic reactions, by preventing the ... by scientists. Researchers hope their finding, published today (Thursday ... allow therapies to be developed that treat allergies by ... a gene known as GATA-3 can block the development ...
... Dec. 26 A lot of Americans take advantage ... to lose weight and live,healthier. There may be a ... that work focus on healthy long-term lifestyle changes., ... Registered journalists can access video, audio, text, graphics ...
... cell research to needle exchanges to medical marijuana and ... science, according to a new book by a leading ... Weill Cornell Medical College. , "Truth, Lies, and Public ... Collide" (Praeger Press, 2007) is authored by Dr. Madelon ...
... results are promising, they don,t address benefits of drug ... treatment that wipes out abnormal heart tissue reduces the ... implanted after heart attacks, a new trial showed. , ... it slips into abnormal rhythms, they are desirable to ...
Cached Medicine News:Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 2Health News:XTENT Submits CE Mark Registration to Market Custom NX(R) Drug-Eluting Stent System in Europe 3Health News:U of M researchers discover fast-acting cyanide antidote 2Health News:Fight against hay fever and other allergies helped by new immune system discovery 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 2Health News:Heart Procedure Reduces Need for Defibrillator Shocks 3
Sera available in three levels for the control of accuracy and precision for up to 31 analytes...
Human based material available in two levels for the control of accuracy and precision for upto 23 analytes....
CRP Liquid Conrtols level 3...
The IRN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of iron in serum....
Medicine Products: